Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00099437 · MORE INFO

Limitations, agreements, and source contact

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. · Source last updated 2026-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The only disclosure restriction on the PI is that they cannot publish any information to do with the trial without written consent from Quintiles.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
aztrial_results_posting@astrazeneca.com
organization
AstraZeneca
title
Gerard Lynch
Complete source fields
certain Agreement
other Details
The only disclosure restriction on the PI is that they cannot publish any information to do with the trial without written consent from Quintiles.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
aztrial_results_posting@astrazeneca.com
organization
AstraZeneca
title
Gerard Lynch

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice